DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.65) by 21.54 percent. This is a 53.21 percent increase over losses of $(1.09) per share from the same period last year. The company reported quarterly sales of $6.80 million which beat the analyst consensus estimate of $6.29 million by 8.11 percent. This is a 12.77 percent increase over sales of $6.03 million the same period last year.
Reported Late Tuesday, Pliant Therapeutics Announces Pricing Of Upsized $250M Public Offering Of 8,333,334 Shares Of Common Stock At A Price Of $30/Share
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized
